From: Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
Diagnose | Gender | Age (year) | FAB type | Cytogenetics | Molecular | WBC (*10^9/L) | HB (g/L) | PLT (*10^9/L) | |
---|---|---|---|---|---|---|---|---|---|
patient 01 | De novo | Female | 69 | M5b | 46, XX | MLL-ELL, NRAS, KARS CSMD1, MECOM | 68.87 | 87 | 29 |
patient 02 | R/R | Female | 74 | M5 | NA | FLT3-TID, NPM1 | 80.94 | 64 | 193 |
patient 03 | De novo | Male | 63 | M2a | Complex karyotype | TP53, NARS | 59.9 | 54 | 23 |
patient 04 | De novo | Female | 55 | M5 | 46, XX | FLT3-TID, DNMT3A | 165.11 | 78 | 115 |
patient 05 | De novo | Female | 44 | M5 | 46, XX, del (8) (q22) | NA | 12.79 | 66 | 10 |
patient 06 | De novo | Male | 34 | M4 | 46, XY | FLT3-TID, DNMT3AIDH1 | 121.7 | 74 | 169 |
patient 07 | De novo | Male | 15 | M5 | Complex karyotype | FLT3, CBFβ-MYH11, NARS | 31.6 | 79 | 22 |
patient 08 | De novo | Female | 50 | M5 | 46, XX | FLT3-TID | 24.57 | 70 | 105 |
patient 09 | De novo | Female | 43 | M1 | 46, XX | WT1, FLT3, IDH2, NPM1 | 33.5 | 80 | 16 |
patient 10 | De novo | Male | 21 | M4 | 47, XY, + mar | NA | 28.17 | 45 | 4 |
patient 11 | R/R | Female | 44 | M2a | NA | WT1, GATA2, CEBPA, KIT | 11.45 | 52 | 15 |
patient 12 | Refractory | Female | 43 | M4 | 46, XX, t (3; 3) (q21; q26) | NA | 91.3 | 43 | 31 |